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The heterodimer S100A8/A9 is potent therapeutic target for idiopathic 
pulmonary fibrosis 
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Short title: Therapeutic potential of S100A8/A9 antibody on IPF 
 




ALCAM: activated leukocyte cell adhesion molecule 
α-SMA: α-smooth muscle actin 
BALF: bronchoalveolar lavage fluid 
BLM: bleomycin 
ECM: extracellular matrix 
EMMPRIN: extracellular matrix metalloproteinase inducer 
EMSA: electrophoretic mobility shift assay 
GVHD: graft-versus-host disease 
H&E: hematoxylin and eosin 
HMGB1: high-mobility group box1 protein 
IHC: Immunohistochemistry 
IPF: idiopathic pulmonary fibrosis 
LAM: lymphangioleiomyomatosis 
MCAM: melanoma cell adhesion molecule 
NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells 
NPTN: neuroplastin 
PDAC: pancreatic ductal adenocarcinoma 
PPH: primary pulmonary hypertension 
RAGE: receptor for advanced glycation end products 




In patients with interstitial pneumonia, pulmonary fibrosis is an irreversible condition 
that can cause respiratory failure. Novel treatments for pulmonary fibrosis are necessary. 
Inflammation is thought to activate lung fibroblasts, resulting in pulmonary fibrosis. Of 
the known inflammatory molecules, we have focused on S100A8/A9 from the onset of 
inflammation to the subsequent progression of inflammation. Our findings confirmed 
the high expression of S100A8/A9 in specimens from patients with pulmonary fibrosis. 
An active role of S100A8/A9 was demonstrated not only in the proliferation of 
fibroblasts but also in the fibroblasts' differentiation to myofibroblasts (the active form 
of fibroblasts). S100A8/A9 also forced fibroblasts to upregulate the production of 
collagens. These effects were induced via the receptor of S100A8/A9, i.e., receptor for 
advanced glycation end products (RAGE), on fibroblasts. The anti-S100A8/A9 
neutralizing antibody inhibited the effects of S100A8/A9 on fibroblasts and suppressed 
the progression of fibrosis in a bleomycin (BLM)-induced pulmonary fibrosis mouse 
model. Our findings strongly suggest a crucial role of S100A8/A9 in pulmonary fibrosis 
and the usefulness of S100A8/A9-targeting therapy for fibrosis interstitial pneumonias. 
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Legend for Graphical Abstract 
In idiopathic pulmonary fibrosis (IPF), S100A8/A9, a heterodimer composed of 
S100A8 and S100A9 proteins, plays a crucial role in the onset of inflammation and the 
subsequent formation of a feed-forward inflammatory loop that promote fibrosis. (1) 
The local, pronounced increase in S100A8/A9 in the injured inflammatory lung 
region — which is provided mainly by the activated neutrophils and 
macrophages — exerts strong inflammatory signals accompanied by dozens of 
inflammatory soluble factors including cytokines, chemokines, and growth factors that 
further act to produce and secrete S100A8/A9, eventually making a sustainable 
inflammatory circuit that supplies an indefinite presence of S100A8/A9 in the 
extracellular space with a mal-increased level. (2) The elevated S100A8/A9 compels 
fibroblasts to activate through receptor for advanced glycation end products (RAGE), 
one of the major S100A8/A9 receptors, resulting in the activation of NFκB, leading to 
fibroblast mal-events (e.g., elevated cell proliferation and transdifferentiation to 
myofibroblasts) that actively produce not only inflammatory cytokines but also collagen 
matrices. (3) Finally, the S100A8/A9-derived activation of lung fibroblasts under a 
chronic inflammation state leads to fibrosis events and constantly worsens fibrosis in 
the lung. Taken together, these findings suggest that the extracellular S100A8/A9 
heterodimer protein is a novel mainstay soluble factor for IPF that exerts many 
functions as described above (1–3). Against this background, we herein applied the 
developed S100A8/A9 neutralizing antibody to prevent IPF. The IPF imitating lung 
fibrosis in an IPF mouse model was effectively blocked by treatment with the antibody, 
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leading to enhanced survival. The developed S100A8/A9 antibody, as an innovative 
novel biologic, may help shed light regarding the difficulties encountered with IPF 




Pulmonary fibrosis is an irreversible condition that is frequently related to a 
number of specific forms of interstitial lung disease. Progressive fibrosis following 
respiratory failure results in death, and the underlying mechanisms (especially in the 
case of idiopathic interstitial pneumonias) are not well understood. One of the major 
forms of idiopathic interstitial pneumonia is IPF (idiopathic pulmonary fibrosis), which 
has a median survival of 3–5 years after the initial diagnosis [1,2]. The histological 
findings of IPF include enriched stroma that fills the space around the alveoli and 
terminal airway as abnormal injury-response lung tissue remodeling, which causes an 
impairment of the body's gas exchange capacity [3,4]. 
Although pirfenidone and nintedanib are approved for the treatment of IPF and 
provide a successful reduction of the decline in forced vital capacity (FVC) and 
prolonged progression-free survival, their effects are not strong enough to completely 
suppress the progressive fibrosis or to significantly improve the patients' prognoses 
[5,6]. Chronic inflammatory condition triggered by lung injury due to known or 
unknown factors is the fundamental pathophysiology of progressive fibrosis [7]. The 
burst of stroma that is mediated by fibrosis is caused mainly by fibroblasts, as 
fibroblasts powerfully produce several matrices composed mostly of collagens when the 
fibroblasts increase in number; the fibroblasts then turn into an active cell type referred 
to as myofibroblasts [3]. Thus, the regulation of fibroblasts may become a useful 
strategy in anti-fibrotic therapy. Notably, pirfenidone, which has shown 
anti-inflammatory and anti-fibrotic potential, suppresses transforming growth 
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factor-beta (TGF-β)-induced myofibroblast differentiation and fibrogenic activity [8]. 
Not enough is known about the molecular mechanism(s) underlying the cellular 
events that take place in fibroblasts such as the burst of proliferation and 
transdifferentiation to myofibroblasts in response to pulmonary fibrosis [9]. It has long 
been suspected that the onset of pulmonary fibrosis and the subsequent feed-forward 
loop formation of the disease resulting in a worsened status are linked to sustained 
inflammation in the lungs [7,10]. Myofibroblasts are highly involved in the 
inflammatory response, as they migrate to the sites of inflammatory injury where they 
proliferate and further produce cytokines, thus enhancing the inflammatory response 
[11]. We therefore turned our attention to S100 family proteins as exceptionally 
attractive target molecules in progressive pulmonary fibrosis, because these proteins are 
closely associated with inflammation and its diverse related diseases. 
S100 proteins comprise 20 family members (S100A1 through 16, B, G, P, and Z) 
with low molecular weights (around 10 kDa), Each S100 protein has Ca2+ binding 
capacity due to an intrinsic EF-hand motif. A typical characteristic of most of the S100 
proteins is a secretory phenotype from many sorts of cells for all not detecting a 
canonical sequence of signal peptide at their N-terminal areas that is present in many 
secretory proteins in general. Interestingly, there is a close association between a high 
expression of S100 proteins and their release and the activity of several inflammatory 
diseases accompanied by fibrosis (e.g., cancer, hepatic cirrhosis, and cardiovascular 
disease) [12-14]. 
In the context of cancer, our research to date has revealed that one of the S100 
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family proteins, i.e., secreted S100A11, plays an important role in the development of a 
dense fibrotic stroma characterized by an abundant accumulation of extracellular 
matrices and fibroblasts of pancreatic ductal adenocarcinoma (PDAC) in the 
surrounding inflammatory microenvironment. S100A11 secreted from PDAC cells 
stimulates their surrounding fibroblasts, leading to their proliferation via receptor for 
advanced glycation end products (RAGE) [15,16]. A variety of inflammatory cytokines 
and chemokines are induced by the activated RAGE upon ligand stimulation, which in 
turn further contributes to an acceleration of fibrosis caused by the stroma enrichment. 
Since RAGE is linked to many S100 family proteins other than S100A11 as its 
ligands, interactions between multiple S100 proteins and RAGE may greatly contribute 
to the onset of fibrosis and its subsequent progression through fibroblast malregulation 
in the broad range of inflammatory diseases accompanied by fibrosis — which may 
include IPF. This hypothesis is supported by the report that in the context of IPF, the 
proliferative remodeling of lung fibroblasts is upregulated by RAGE upon ligand 
binding [17,18]. 
Among the 20 S100 family proteins [19], S100A8/A9, a heterodimer complex of 
S100A8 and S100A9, gained our attention because S100A8/A9 is closely associated 
with a broad range of inflammatory pathogeneses in the lung respiratory tract [20]. We 
have been investigating the role(s) of S100A8/A9 in lung tropic cancer metastasis and 
have attempted to generate an effective method to prevent cancer metastasis via the 
regulation of S100A8/A9 [21-26]. In the process of those investigations, we newly 
developed anti-S100A8/A9 neutralizing antibody clone #45, which greatly suppressed 
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not only lung tropic cancer metastasis but also lung inflammation via an effective 
inhibition of the induction of diverse inflammatory cytokines stimulated by S100A8/A9 
[27]. 
Considering the previous results together with our prior finding of a marked 
increase in S100A8/A9 in the lungs of patients with IPF as described below in the 
Results, we hypothesized that the developed anti-S100A8/A9 antibody could suppress 
pulmonary fibrosis and IPF progression. This hypothesis is supported by the relevant 
literature regarding IPF and lung fibroblasts, which can be summarized as follows (1). 
S100A9 is markedly elevated in the bronchoalveolar lavage fluid (BALF) in IPF, and 
the S100A9 level is currently recognized as a reliable biomarker for IPF [28,29]. (2) 
S100A9 acts as a strong mitogen for fibroblasts in chronic inflammation through RAGE. 
(3) In the human body, most of the S100A9 protein exists as a heterodimer with 
S100A8 and not as single monomeric form [30]. Thus, an elevated S100A8/A9 level 
may play a crucial role in the pathogenesis of IPF via enhanced and sustained 
inflammation and the proliferation of fibroblasts in the lungs' intratissue environment. 
We thus conducted the present study to evaluate the potential causative role of 
S100A8/A9 in pulmonary fibrosis and the therapeutic potential of the developed 




The production and release of S100A8/A9 are upregulated in IPF 
To investigate the possible relationship between S100A8/A9 and IPF, we first 
performed immunostaining of S100A8/A9 in the resected lung specimens of patients 
with IPF. As shown in Figure 1a, we observed that compared to the normal healthy lung 
specimens (top), S100A8 and S100A9 were both highly positive in the stroma-abundant 
area in the patients' lung specimens (bottom). To more accurately quantify the 
expressions of S100A8 and S100A9 in the lung specimens of IPF, we further carried 
out a western blot (WB) analysis and ELISA of the proteins. The WB data clearly 
showed that at the protein level, the expressions of both S100A8 and S100A9 were 
markedly higher in the IPF lungs compared to the normal specimens (Fig. 1b). Similarly, 
S100A8 and S100A9 were significantly elevated in the IPF patient plasma (Fig. 1c). Of 
interest, S100A8 and S100A9 were also markedly upregulated in the plasma from 
patients with other types of pulmonary fibrosis (PF) that are not diagnosed as IPF. No 
any appreciable alteration or elevated trend was observed at the protein level in the 
plasma from patients with other lung diseases such as graft-versus-host disease 
(GVHD) after bone marrow transplantation, lymphangioleiomyomatosis (LAM), and 
primary pulmonary hypertension (PPH). 
It has long been recognized that the levels of S100A8/A9 are highly elevated 
under an inflammation setting [20], and we therefore examined the state of a 
well-known inflammatory biomarker, NFκB (nuclear factor kappa-light-chain-enhancer 
of activated B cells), in the lungs of the IPF patients. In agreement with the increased 
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patterns of S100A8 and A9, we observed that NFκB was markedly upregulated in the 
lung specimens from IPF patients (Fig. 1d). These results suggest that lungs with IPF 
are in a serious and chronic inflammation state. 
 
Extracellular S100A8 and S100A9 activate multiple cellular events of fibroblasts 
relevant to the pathogenesis of fibrosis 
To determine the roles of S100A8 and S100A9 in the growth of fibroblasts, we next 
stimulated mouse and human fibroblasts with purified recombinant S100A8 and 
S100A9 protein (see Materials and Methods) in culture. The stimulated mouse 
fibroblasts showed increased growth activity as evaluated by both an MTS assay (Fig. 
2a) and the EdU uptake (Fig. 2b, left). The 100 ng/ml concentrations of S100A8 and 
S100A9 resulted in the strongest induction of DNA synthesis in the culture setting. The 
S100A8 and S100A9-mediated upregulation of growth was RAGE-dependent, since 
S100A8/A9 never stimulated the growth of RAGE-negative fibroblasts (Fig. 2b, 
middle). We further confirmed that the S100A8/A9-mediated growth stimulation was 
not restricted to mouse cells, because the DNA synthesis in normal MRC-5 fibroblasts 
originated in the human lung was also activated by S100A8 and S100A9 (Fig. 2b, 
right). 
As we mentioned above, NFκB is a well-known transcription factor that is highly 
associated with the onset of inflammation and the subsequent progression. Its activation 
is regulated by the RAGE-mediated signal cascade [31]. Since the activation of NFκB 
leads to cell survival and growth and the production of inflammatory cytokines [32], we 
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attempted to determine whether NFκB would be activated in fibroblasts through RAGE 
upon S100A8 and S100A9 binding. As shown in Figure 2c, we observed that the DNA 
binding activity of NFκB was upregulated in mouse fibroblasts in response to the 
S100A8/A9 stimulation; the activation peak appeared at 6 h after the stimulation. 
We also confirmed that the S100A8/A9-mediated functional activation of NFκB 
was significantly mitigated in RAGE-negative mouse fibroblasts (Fig. 2d, left). To 
investigate whether anti-S100A8/A9 antibody (clone #45) can remove the ability to 
activate NFκB, we performed that same experiments under the presence of the antibody. 
The results demonstrated that clone #45 but not the control IgG efficiently blocked the 
activation of NFκB induced by the S100A8/A9 stimulation of mouse fibroblasts (Fig. 
2d, left). These results were also reproduced in a similar experiment using other human 
MRC-5 fibroblasts (Fig. 2d, right). 
Considering the physiological context, S100A8 and S100A9 emerge as their 
heterodimer complex, whereas the individual homodimer composed of single S100A8 
or S100A9 is considered to present at lower levels than the S100A8/A9 heterodimer 
[30]. To confirm the specificity of clone #45 to S100A8/A9 but not the homodimer 
from single S100A8 or S100A9, we attempted immunoprecipitation (IP) with clone #45 
to the human IPF lung specimen. We first checked the reactivity of clone #45 to the 
prepared recombinant proteins of human origin (S100A8, S100A9, S100A8/A9) (Suppl. 
Fig. S1a), which are approx. 20 kDa and probably included dimers in most of the native 
PAGE gel (data not shown). In the IP experiments (Suppl. Fig. S1b), clone #45 
efficiently trapped S100A8/A9 but not both S100A8- and S100A9-derived dimers. 
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The specific reaction of clone #45 to S100A8/A9 was then confirmed with lung 
tissue extracted from an IPF patient, in a competitive assay with the added foreign 
S100A8 and S100A9 dimers. The assay results revealed that the ability of clone #45 to 
capture the endogenous S100A8/A9 in the IP procedure was not lowered by the excess 
amount of foreign S100A8 or S100A9 dimer (Suppl. Fig. S1c). On the other hand, as 
we expected, the precipitated S100A8/A9 was highly elevated in a dose-dependent 
manner according to the added foreign S100A8/A9. 
We further examined the specific neutralization activity of clone #45 against 
S100A8/A9. As shown in Figure 2e, the NFκB activity in the mouse fibroblasts 
stimulated with S100A8/A9 but not with the S100A8 or S100A9 dimer was effectively 
blocked by the treatment with clone #45. Notably, we also observed that the NFκB 
activity induced by the stimulation with S100A8/A9 was the highest among the stimuli 
used, supporting the idea that S100A8/A9 has much higher activity than each dimer 
composed of either S100A8 or S100A9, at least in fibroblasts. These results combined 
with our previous findings regarding S100A8/A9 function [25,33] and clone #45's 
specificity to S100A8/A9 [27] indicate that S100A8/A9 exerts much higher activity to 
lead to inflammation compared to that of S100A8 or S100A9 dimer, and that clone #45 
selectively recognizes S100A8/A9 heterodimer with efficient neutralizing activity. 
In the present IPF patients, the average concentration of S100A8/A9 was elevated 
to 5.2 µg/ml (and to 14.4 µg/ml at the maximum) (Fig. 1c). Considering the physiology 
of IPF, we then examined the effects of such a high dose of S100A8/A9 on fibroblasts. 
We challenged cultures of mouse fibroblasts with S100A8/A9 at the dose range of 0–
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10,000 ng/ml (in 10 µg/ml increments) and examined the activity of NFκB in the 
stimulated fibroblasts. A clear band showing NFκB activation was detected starting 
from the 10 ng/ml dose; the activity reached its peak at 100 ng/ml, and the highest level 
of activity was also maintained at the increased doses of 1,000 and 10,000 ng/ml (Suppl. 
Fig. S2). These results suggest that an inflammatory response of fibroblasts occurs 
physiologically in IPF patients. 
The transition of fibroblasts to myofibroblasts contributes greatly to the 
remodeling of the extracellular space towards fibrosis. Since NFκB activation works to 
promote myofibroblasts' differentiation from fibroblasts [34,35], we next studied this 
subject by focusing on the S100A8 and S100A9-RAGE-NFκB axis. To evaluate the 
degree of differentiation, we examined the expression level of α-smooth muscle actin 
(α-SMA) protein by performing a western blot analysis. Notably, we observed that 
S100A8 and S100A9 act to increase the percentages of α-SMA-positive mouse 
fibroblasts and human MRC-5 fibroblasts, and this event was effectively blocked by the 
presence of clone #45 but not control IgG (Fig. 2f). The S100A8/A9-mediated 
myofibroblast differentiation was dependent on RAGE, since no any appreciable 
alteration of α-SMA expression at the protein level was observed in RAGE-negative 
mouse fibroblasts. 
In light of the increased production ability of the extracellular matrix in 
myofibroblasts, we evaluated the expression levels of collagens in the 
S100A8/A9-derived myofibroblasts. As shown in Figure 2g, we confirmed the 
upregulated production of some types of collagens in the S100A8/A9-stimulated 
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wildtype cells but not in RAGE-negative cells. In addition, the induction of collagens in 
the wildtype cells was clearly suppressed by the addition of clone #45. These results 
indicate that S100A8 and S100A9 play a crucial role in not only the proliferation burst 
of fibroblasts but also their transdifferentiation to myofibroblasts via RAGE. 
 
The production and release of S100A8/A9 were upregulated in the mouse IPF 
model, and therapy targeting the S100A8/A9-RAGE axis showed high potential to 
cure the model IPF 
To evaluate the therapeutic effect of clone #45 on IPF, we used a well-established 
mouse model of IPF, i.e., the bleomycin (BLM) model of pulmonary fibrosis. We first 
attempted to determine whether S100A8 and/or S100A9 are elevated in IPF-imitated 
model mice. After exposure of the mice to BLM (Fig. 3a), we observed that S100A8/A9 
heterodimer complex was significantly upregulated in the lungs starting from day 1 of 
the exposure, and the protein levels were further elevated by day 7 (Fig. 3b, top). In 
parallel with this, the S100A8/A9 level was also greatly increased in the plasma with a 
time course pattern that was similar to that observed in the lungs except for the day 1 
data (Fig. 3b, bottom). 
In concert with the elevation trend of S100A8/A9 level in the lungs (Fig. 3b, top), 
the NFκB activities in the same lung specimens of BLM-treated mice also showed a 
pattern that was similar to that of S100A8/A9; in addition, the highest activities of 
NFκB also appeared on day 7. We thus designated day 7 as a serious inflammation 
point in the IPF model (Fig. 3c). 
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On day 7, which showed a trend of the highest levels of S100A8/A9 protein and 
NFκΒ activity in common, we confirmed that the expressions of both S100a8 and 
S100a9 genes were also increased in the lungs, at notably high levels (Fig. 3d). The 
increase in the expression of Ager gene (mouse RAGE) was accompanied by increases 
in the expressions of S100a8 and S100a9 on day 7, suggesting that an activation of the 
S100A8/A9-RAGE axis is caused in the IPF model, similar to the in vitro situation we 
observed (Fig. 2). 
Bearing these results in mind, we then sought to determine the effect of 
S100A8/A9 antibody clone #45 on the IPF model according to the evaluation schedule 
shown in Supplementary Figure S3a. We again induced pulmonary fibrosis in mice by 
treatment with BLM, and subsequently anti-S100A8/A9 antibody or control IgG was 
administered on Day 0 at a dose of 100 µg and on Day 14 at a dose of 50 µg. We 
observed that clone #45 showed the trend towards blocking the BLM-induced serious 
decrease in the body weight (Suppl. Fig. S3b) and survival rate (Suppl. Fig. S3c) of the 
mice compared to the results with control IgG. Under these conditions, we quantified 
the degree of pulmonary fibrosis in mice by computed tomography (CT), which 
confirmed that the BLM-induced fibrosis also showed a diminished tendency by the 
treatment with clone #45 compared to the use of control IgG (Suppl. Fig. S3d). 
 
The S100A8/A9 neutralizing antibody worked very efficiently to prevent the model 
IPF 
To evaluate the dose dependency of the therapeutic effect of clone #45, we conducted 
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experiments that were similar to those whose results are shown in Supplementary 
Figure S3 (Fig. 4a). The results confirmed that clone #45 effectively blocked the 
BLM-induced serious decrease in the body weight (Fig. 4b) and survival rate (Fig. 4c) 
of the mice in a dose-dependent manner, and the highest dose (500 µg) in this context 
showed no lethality. The results of the CT analysis confirmed the dose-dependent 
suppression of BLM-induced fibrosis, which was consistent with the evaluation results 
of the body weight and survival rate (Fig. 4d). 
We also assessed the lung histological compositions of the treated mice and 
found that the dense stromal area caused by BLM exposure was effectively reduced by 
the treatment with clone #45 at the doses of 200 µg as well as 500 µg, and the histology 
images were very similar to those of the structure in the normal lung (Fig. 4e). The 
antibody (clone #45)-mediated cure events in histology were accompanied by the 
attenuated staining patterns with Masson's trichrome, suggesting an effective 
suppression of the collagens' production in the groups treated with clone #45. 
Under the observed healing context with the antibody, we evaluated the condition 
of IPF-relevant matrix expression. The quantitative real-time PCR analysis showed that 
clone #45 significantly reduced the expressions of Col1a1 (mouse collagen type I alpha 
1 chain) and Fn1 (mouse fibronectin) but not that of Col3a1 (mouse collagen type III 
alpha 1 chain) gene. The myofibroblast differentiation marker Acta2 (mouse α-smooth 
muscle actin: α-SMA) gene was also significantly decreased by the treatment with 
either dose of clone #45 (Suppl. Fig. S4). The PCR and EMSA analyses using the 
harvested whole lung specimens on day 7 revealed that treatment with clone #45 at the 
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highest dose (500 µg) (Suppl. Fig. S5a) tended to prevent the elevation of IPF-relevant 
inflammatory factors and extracellular matrices in the cases of Ccl2, Nos2 (iNOS), 
Tgf-b1, Pdgfa, Col1a1, Col3a1, and Fn1 (Fig. 4f), but not Il-1b, Il-4, Il-12a, Il-13, or 
Tnf-a (Suppl. Fig. S5b). Among these, the BLM-induced elevations of the extracellular 
matrices Col1a1 and Fn1 in gene expression (Fig. 4f) and NFκB activation were 
significantly suppressed by the treatment with clone #45 (Fig. 5). Clone #45 reduced the 
basal level of the cytokine Il-6, which was not upregulated by the BLM treatment.  
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DISCUSSION 
Our present findings demonstrated that S100A8 and S100A9 are significantly 
upregulated in individuals with IPF. These increases also occur in other fibrosis 
diseases in the lung (PFs) but not GVHD, LAM, or PPH. Malfunctions of lung 
fibroblasts contribute greatly to pulmonary fibrosis. Our mechanistic approaches 
revealed a crucial role of S100A8/A9 on fibroblasts in the fibrosis setting through an 
S100A8/A9 receptor, RAGE, which is present on the membrane surface of lung 
fibroblasts. The RAGE activation in fibroblasts stimulated by the abundant extracellular 
S100A8/A9 is linked to a strong activation of NFκB, which plays a crucial role in the 
induction of several inflammatory cytokines, the promotion of growth, the acceleration 
of differentiation to myofibroblasts, and the increased expression of main stroma 
components, collagen and fibronectin. 
In light of those findings, we suspected that a blocker of the S100A8/A9-RAGE 
axis could prevent IPF via the suppression of NFκB. Our S100A8/A9 antibody clone 
#45 effectively suppressed not only several activation events of fibroblasts in culture 
(such as the activation of NFκB and the inductions of α-SMA and collagens); clone #45 
also suppressed the actual pulmonary fibrosis in the BLM-mediated IPF model. These 
results indicate that the S100A8/A9-RAGE axis plays an unusual role in the onset of 
IPF and its subsequent progression, and we speculate that targeted therapy using 
S100A8/A9 antibody or another antibody related to that axis may lead to a breakthrough 
for therapeutic strategies for IPF, which has been extremely difficult to treat. 
The RAGE-mediated upregulation of the proliferation activity of fibroblasts may 
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be due in part to the enhanced MyD88-mTOR-p70 S6 kinase signal cascade 
downstream of RAGE upon ligand binding, which we identified under different 
experimental settings [36]. A report by Yin et al. supports this idea, since they revealed 
that aloperin (a quinolizidine alkaloid extracted from Sophora alopecuroides) acted very 
effectively to cure mice of their BLM-induced pulmonary fibrosis by an attenuation of 
fibroblasts' proliferation via a repression of mTOR signaling [37]. In addition, Mercer et 
al. described the importance of the signal pathway leading to mTOR activation as a 
promising therapeutic target in IPF [38]. 
As seen in Figure 2, the S100A8/A9-mediated NFκB activation might not depend 
on a single RAGE, since NFκB was activated at a lower level in the RAGE-negative 
cells compared to the wildtype cells. We previously identified other important receptors 
for cancer metastasis, i.e., extracellular matrix metalloproteinase inducer (EMMPRIN) 
[21], neuroplastin (NPTN) α and β (NPTNβ compensates for NPTNα) [22], activated 
leukocyte cell adhesion molecule (ALCAM), and melanoma cell adhesion molecule 
(MCAM) [23]. We named this group of receptors the "novel S100 soil sensor receptors 
(novel SSSRs)" [25,33]. In light of the expression of these SSSRs in fibroblasts, we 
suspect that SSSRs other than RAGE may have contributed to the observed NFκB 
activation in the RAGE-negative cells in response to S100A8/A9. The contributions of 
other SSSRs to IPF will be the focus of our next investigations of how these receptors 
are mutually involved in the onset and progression of IPF. 
The therapeutic effect of these biologics in IPF may be based on features other 
than the suppression of fibroblasts. Our research into the ability of exRAGE-Fc to 
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prevent the lung tropic metastasis of cancer cells revealed important information about 
the lung state in the tumor-bearing mice [25]. In that setting, we observed that the high 
levels of the induction of inflammatory soluble factors (e.g., Mmp12, Mmp13 and 
Pla2g2d), an interleukin (Il33), chemokines (Ccl19, Ccl1, Ccl2, Ccl5, Ccl8, Ccl12, 
Ccl21, Cxcl12 and Cxcl5/6), and complement factor C5 in the mouse lungs caused by 
the transplanted cancer were effectively blocked by treatment with exRAGE-Fc [25]. 
In the present study, we observed that the S100A8/A9 antibody clone #45 tended 
to suppress IPF-relevant inflammatory factors such as Ccl2, iNos, Tgf-β, Pdgfa and Il-6. 
Among these suppressed factors, the trend of a reduced Tgf-β level is interesting since it 
directly stimulates fibroblasts' proliferation and the differentiation of fibroblasts into 
aggressive myofibroblasts, which are responsible for the active production of 
extracellular matrix [4]. Considering that the production and secretion of these multiple 
soluble factors occur not only in fibroblasts but also other lung cells including epithelial 
cells, endothelial cells, monocytes, neutrophils and more [39], we speculate that the 
S100A8/A9-RAGE axis may broadly regulate lung inflammation by stimulating 
multiple types of cells in the lungs; targeting this axis could dominate all of these cells 
at the same time [40] and a suppression of IPF might thereby occur when S100A8/A9 
antibody is used in vivo. 
Due to the presence of multiple ligands for RAGE that are not limited to 
S100A8/A9, other ligand(s) may also cooperatively stimulate RAGE with S100A8/A9 
on fibroblasts in the IPF setting. Hamada et al. reported that high-mobility group box1 
protein (HMGB1), one of the major ligands of RAGE, is significantly increased in the 
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BALF of IPF patients [41,42]. In a finding that is consistent with our results, they 
revealed that extracellular HMGB1 stimulates proliferation and collagen synthesis on 
the cultured fibroblasts. In addition to their in vitro results, Hamada et al. also reported 
that anti-HMGB1 antibody works well to prevent BLM-mediated pulmonary fibrosis in 
mice. Thus, other ligands such as HMGB1 also functionally work in the disease onset 
and subsequent progression of IPF [43]. In fact, our exRAGE-Fc decoy (which is 
thought to capture all RAGE ligands including HMGB1 at the same time) showed a 
tendency to prevent IPF in a mouse BLM model, but the suppressive effect of the decoy 
was weaker than that of the anti-S100A8/A9 antibody in our experimental context, 
suggesting that S100A8 and S100A9 may play major roles in IPF disease through 
RAGE (Suppl. Fig. S6). However, this result does not sufficiently support a genuine 
inhibitory potential of the exRAGE-Fc decoy since we did not use a higher dose of the 
decoy in vivo than the indicated 100 µg at that time (Suppl. Fig. S6); this subject is part 
of our ongoing research.  
Here, how about the targeting potential of RAGE side but not ligands side using 
RAGE inhibitors [44,45] as another approach? It is somehow controversial for the 
blocking of RAGE in the IPF therapy. It has reported that RAGE expression is 
significantly downregulated in human IPF lungs and RAGE-null mice spontaneously 
develop pulmonary fibrosis with age and develop more severe fibrosis when challenged 
with asbestos [46]. The reciprocal event in the RAGE-null mouse to our results may be 
due to a contribution of RAGE-like receptors, i.e., novel SSSRs. Interestingly, we found 
that MCAM expression is markedly upregulated in RAGE-null fibroblasts compared to 
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its expression in WT fibroblasts [36]. We hence consider that MCAM may act as 
another S100A8/A9 receptor like RAGE in a compensatory manner in IPF settings so 
that the targeting of ligand side may be better than the receptor side in the difficult IPF. 
Since there are inclusive SSSRs other than RAGE and the presence of multiple ligands 
for S100A8/A9 in addition to RAGE [47,48], further studies will unravel one by one the 
very complex relationship among these molecules on single lung fibroblasts and the 
multiple type of cells surrounding them. With the use of the inclusive SSSRs and their 
ligands, such studies will eventually lead to a comprehensive understanding of the 
mutual cross-talk among the disease-relevant cells and molecules in the enigmatic 
disease that IPF presents. 
In conclusion, our present findings identified the S100A8/A9-RAGE axis in 
fibroblasts as a potent therapeutic target for IPF. Our novel S100A8/A9 antibody clone 
#45 shows high potential to become a useful drug in the clinical settings of IPF. 
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MATERIALS AND METHODS 
Cells 
Details are provided in Supplementary Materials and Methods. 
 
Recombinant proteins 




Mouse monoclonal anti-S100A8/A9 neutralizing antibody (clone #45) was developed 
by us as described [27] and prepared for the present study. 
 
Study population 
Plasma samples were obtained just before surgery from patients about to undergo lung 
transplantation. Lung tissue samples for western blotting and immunohistochemistry 
(IHC) were obtained from patients who had already undergone lung cancer surgery; 
lung tissues of these patients were interpreted as showing non-malignant areas and IPF 
lesions that were both located far from the defined area of lung cancer. These 
characteristics are summarized in Table 1. A series of specimens as described above 




Histopathology and immunohistochemistry 
The protocol for the IHC staining was as described [50]. Details are provided in 
Supplementary Materials and Methods. 
 
Western blot analysis 
Details are provided in Supplementary Materials and Methods. 
 
ELISA 
The protein levels of S100A8/A9 in the lung extracts collected from the patients were 
evaluated by monitoring S100A8/A9 in the specimens with an enzyme-linked 
immunosorbent assay (ELISA) in a comparison with the levels in specimens from 
normal healthy donors. The characteristics of the patients are summarized in Table 1. 
The human S100A8/A9 ELISA was performed under conventional conditions using 
mouse anti-human S100A8/A9 antibody (clone #45 and clone #260) developed by us as 
described [27]. 
The protein levels of mouse S100A8/A9 protein in the plasma and lung samples 
from the mice were evaluated by a Sandwich ELISA method (Mouse Calprotectin 
ELISA Kit, LifeSpan Biosciences, Seattle, WA) in accord with the manufacturer's 
instructions. 
 
Quantitative real-time PCR 
Details are provided in Supplementary Materials and Methods. 
28 
 
Cell growth assay 
Details are provided in Supplementary Materials and Methods. 
 
Electrophoretic mobility shift assay (EMSA) 
Details are provided in Supplementary Materials and Methods. 
 
Animal experiments 
All mice procedures and euthanasia were done with the mouse painlessly or under 
anesthesia, strictly following the Committee's guidelines. The detail methods are 
provided in Supplementary Materials and Methods. 
 
Statistical analyses 





K.A. established the methodology, designed and performed most of the experiments, 
and analyzed the data. R.K. prepared S100A8/A9 antibody and performed the ELISA 
and PCR experiments. N.T. and Y.G. assisted with most of the animal experiments and 
assisted K.A. in the data evaluation. S.T. contributed to the data analysis and its 
evaluation and validation. Y.T., S.S., K.S. K.S., H.Y. M. O., S.S., K.I. contributed to the 
collection of the series of biomaterials. A.T. and N.M. contributed to the establishment 
of the animal model and assisted K.A. with some of the animal experiments. K.Y. and 
H.M. performed the primary cell culture and participated in the confirmation of some of 
the data of the in vitro cell assays. M.S. performed the immunoprecipitation, western 
blot analysis and EMSA, and M.N. assisted M.S.’s experiments. S.T and M.S. designed 
and supervised the project and wrote, reviewed and edited the manuscript.	
 
Funding 
This research was supported by grants from the Acceleration Transformative Research 
for Medical Innovation (ACT-M) in the Japan Agency for Medical Research and 
Development (AMED) (no. JP20im0210119) and the JSPS KAKENHI (no. 17H03577 to 
M.S.; no 19H03746 to S.T.) and by funds to M.S. from the Smoking Research 
Foundation, the Terumo Life Science Foundation, and the Takeda Science Foundation. 
 
Acknowledgements 
We thank Dr. Shin Morizane and Dr. Tomoko Miyake (Department of Dermatology, 
30 
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences) for the preparation of the psoriasis patients' skin tissue sections used herein as 
a representative positive control for evaluating the S100A8/A9 staining. We also 
gratefully acknowledge Dr. Seiichi Tanida (Advanced Science, Technology and 
Management Research Institute of Kyoto) and Dr. Michiaki Mishima (Kyoto 
University) for their critical advice to this study. 
 
Compliance with ethical standards 
A couple of studies using clinical specimens (tissues and blood samples) were approved 
by the Okayama Medical School and Hospital's Research Ethics Committee. The 
approved numbers are as follows: # 1910-017 and # 1906-033. Informed consent was 
obtained from individual patients for the use of their materials. Experimental protocols 
required for the animal studies were approved by the Animal Experiment Committee at 










Fig. 1. Upregulation of S100A8/A9 in the lung with IPF. a: Immunostaining of 
S100A8/A9 was performed in the tissue sections from an IPF patient-derived lung 
lesion (bottom) in a comparison with sections from normal lung tissues (top). b,c: To 
quantify the expression and secretion levels of S100A8/A9 in the IPF patients, western 
blotting (b) and ELISA (c) of S100A8/A9 were carried out using the lung tissue extracts 
and plasma samples, respectively. d: The NFκB activation levels were examined by 
EMSA, using the same set of lung extracts from healthy donors (normal) and IPF 
patients (IPF) that was prepared in panel b. 
 
Fig. 2. The effect of S100A8/A9 on fibroblasts in culture. a–c: Growth activities of 
fibroblasts were monitored by an MTS assay (a) and the EdU intake (b) after 
stimulation of the cells with recombinant S100A8/A9 at the final concentration range of 
0–100 ng/ml (see the indicated doses) for 24 h. In these experiments, mouse primary 
lung fibroblasts (wild [WT] and RAGE negative [−/−]) (a,b, left) and human lung 
primary MRC-5 fibroblasts (b, right) were used. c,d: An EMSA was carried out to 
evaluate the NFκB activation levels in fibroblasts. Mouse WT fibroblasts were 
stimulated by S100A8/A9 at a final concentration of 100 ng/ml for the indicated time 
intervals (c). Mouse fibroblasts (WT and RAGE−/−) and human MRC-5 fibroblasts were 
treated with S100A8/A9 (100 ng/ml) for 6 h under the presence of the clone #45 or 
control IgG (1000 ng/ml) (d). e: Mouse WT fibroblasts were treated with S100A8, 
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S100A9, or S100A8/A9 at a final concentration of 100 ng/ml for 6 h under the presence 
of clone #45 or control IgG (1,000 ng/ml), and the treated samples were then all 
subjected to an EMSA analysis to evaluate the NFκB activity. f: Mouse fibroblasts (WT 
and RAGE−/− ) and human MRC-5 fibroblasts were also treated with S100A8/A9 (100 
ng/ml) for 48 h under the presence of clone #45 or control IgG (1000 ng/ml). After the 
treatments, the cell pellets were collected, lysed and subjected to western blotting to 
evaluate the expression of the myofibroblast marker α-SMA. g: The same specimens of 
mouse fibroblasts prepared in panel f were also subjected to western blotting for the 
evaluation of the expression of collagens by using the biotin-labeled denatured-collagen 
hybridizing peptide. Data are mean±SD. *p<0.05, **p<0.01, ***p<0.001. 
 
Fig. 3. Increase in S100A8/A9 in the BLM-induced mouse IPF model. a: Time 
schedule of the experimental induction of IPF in mice by bleomycin (BLM) 
administration. b: According to the experimental schedule, one-half of the whole lung 
nuggets and blood specimens were collected from each treated mouse on the indicated 
days (Days 0, 1, 3, 7, and 21) and the lung protein extracts (top) and plasma (bottom) 
were then prepared from the collected biomaterials. The prepared specimens were 
subjected to an ELISA to monitor the S100A8/A9 contents. c: An EMSA was 
performed to evaluate the NFκB activation levels in the resected lung extracts from the 
BLM-treated mice on the indicated days (0, 1, 3, 7, and 21). d: A quantitative real-time 
PCR analysis was done by using the remaining one-half of the whole lung specimens 
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that were prepared on days 0 and 7 in order to detect S100a8, S100a9, and Ager (mouse 
RAGE) genes. Data are mean±SE. *p<0.05, **p<0.01, ***p<0.001. 
 
Fig. 4. The dose-dependent effect of anti-S100A8/A9 neutralizing antibody clone 
#45 on IPF symptoms in the BLM-induced mouse IPF model. a: Time schedule of 
the experimental induction of IPF in mice by BLM and by a single treatment with clone 
#45 at the concentrations of 0, 200, and 500 µg. The antibody was applied a single time 
1–2 h after the BLM treatment representing day 0. b: According to the experimental 
schedule, body weights were monitored and are shown as box plots on Days 7, 14, and 
21. Black circles show dead mice. c: Overall survival plots through the experimental 
time line as shown in panel a. d: On day 21, the mouse lungs were monitored by a 
determination of the CT scan-based fibrosis area in the whole lung. Top panels: The CT 
images. Bottom panels: The quantified result (bar graph) for the high-density areas in 
the lungs that are shown by red color (the image is representative one). e: On day 21, 
H&E or Masson's trichrome staining was also performed with the tissue sections from 
the prepared lungs of the treated mice for the evaluation of the lung intratissue 
composition and collagen stacking, respectively. f: A quantitative real-time PCR 
analysis was done for the resected lung specimens that were collected on day 7 to detect 
the indicated IPF-related genes. Data are mean±SE. *p<0.05, **p<0.01, ***p<0.001. 
 
Fig. 5. The effect of anti-S100A8/A9 neutralizing antibody clone #45 on NFκB 
activity in the BLM-induced mouse IPF model. For the evaluation of NFκB activity, 
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we performed an EMSA using the resected lung specimens collected from the 
BLM-treated mice on day 7 that were co-treated or not co-treated with clone #45 (500 
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